12
↑0
↓12
—0
Evidence suggests Psilocybin maydecreaseDepression.
12 studies (12 claims)
Exact normalized-entity scope. Exact scope. Claims must match the selected normalized intervention and endpoint IDs; signal links are not expanded. Direction describes the stored endpoint phrase and is not a benefit/harm judgement.
14 of 14
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psilocybin | Decreases - highly promising preliminary data have been produced | depression | Human | — | Not specified | Psychedelic drugs-a new era in psychiatry? .cited 53× |
| psilocybin | Decreases - reduction | depression | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.cited 59× |
| psilocybin | Decreases - suggesting a rapid antidepressant effect sustained | depression | Human | some responders | Not specified | Psychedelics for treatment resistant depression: are they game changers?cited 5× |
| psilocybin | No effect - remission rate is | depression | Human | participants | Not specified | Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.cited 4× |
| psilocybin | Decreases - much smaller remission rate | depression | Human | more than 100 depressed participants in larger Phase II trials | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |
| psilocybin | No effect - merit rigorous replication studies | depression | Human | — | Not specified | Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.cited 3× |
| psilocybin | Decreases - can be used as a fast-acting antidepressant | depression | Molecular | clinical and preclinical studies | Not specified. | Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.cited 1× |
| psilocybin | Decreases - superior in treating depression | depression | Human | — | Not specified | Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.cited 2× |
| psilocybin | Decreases - addressing conditions | depression | Human | patients with chronic pain | Not specified | Psilocybin as a novel treatment for chronic pain. |
| psilocybin | Decreases - document the efficacy | depression | Human | patients with medically refractory depression | Not specified | Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. |
| psilocybin | Decreases - revealed a strong effect | depression | Human | — | Not specified | Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. |
| psilocybin | Decreases - demonstrated the efficacy in reducing symptom severity | depression | Human | — | Not specified | Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.cited 2× |
| psilocybin | Decreases - moderately superior to controls at reducing | depression | Human | participants | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |
| psilocybin | Decreases - demonstrates significant reduction relative to controls | depression | Human | — | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |